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OBJECTIVE: Several innovative imaging modalities, includ-
ing endoscopic ultrasound, have increased the number of
available preoperative staging methods in patients with ad-
enocarcinoma of the pancreas. Our goal was to estimate the
clinical outcomes and cost-effectiveness of alternative stag-
ing strategies for pancreatic adenocarcinoma.
METHODS: Decision analysis was used to simulate alterna-
tive staging strategies. Cost inputs were based on Medicare
reimbursements; clinical inputs were obtained from the
available literature. Model endpoints of interest were cost
per curative resection and appropriateness of treatment al-
location based on pathological stage.
RESULTS: Endoscopic ultrasound followed by laparoscopy
yielded the lowest cost per curative resection ($37,600) and
minimized the number of unnecessary surgical explorations
(5.4 per 100 patients staged). Requiring angiographic con-
firmation when endoscopic ultrasound demonstrated an un-
resectable tumor yielded an intermediate cost-effectiveness
ratio and virtually eliminated the risk of overstaging. Lapa-
roscopy alone maximized the resection rate, but each addi-
tional resection would cost approximately $2 million rela-
tive to a strategy employing both endoscopic ultrasound and
angiography.
CONCLUSIONS: Staging strategies incorporating endoscopic
ultrasound may improve treatment allocation and are cost-
effective relative to angiography-based strategies. A staging
protocol that does not incorporate an imaging modality to
detect vascular invasion dramatically increases the cost per
additional curative resection compared with more compre-
hensive staging protocols. (Am J Gastroenterol 2000;95:
1708–1713. © 2000 by Am. Coll. of Gastroenterology)
INTRODUCTION
Adenocarcinoma of the pancreas is the fifth leading cause of
cancer death in the United States and approximately 27,000
new cases are diagnosed annually (1). Disease is usually
advanced at the time of diagnosis and only 15% of patients
have localized tumors amenable to attempted curative re-
section (2–7). The recent reports of 5-yr postresection sur-
vival rates of.20% and surgical mortality rates of,5%
(8–11) have re-emphasized the need to consider surgical
resection as a therapy with curative potential.
The prognosis for the 85% of patients with unresectable
disease remains dismal. The median survival in this group is
6 months and the primary therapeutic goal is palliation (12,
13). Despite improvement in postoperative outcomes after
curative resection, the operative mortality and morbidity for
palliative surgery remains high (14, 15). Several random-
ized trials have demonstrated endoscopic biliary endopros-
thesis placement to be equal in efficacy to surgical biliary
bypass for relief of obstructive jaundice (16–19). In addi-
tion, endoscopic palliation is associated with significantly
lower morbidity and mortality rates and may shorten the
length of hospitalization relative to surgical interventions.
Although surgical bypass remains the treatment of choice
for duodenal obstruction, this is frequently a terminal event
and fewer than 10% of patients will be candidates for
duodenal bypass during the course of the disease (16).
Therefore, the majority of patients with unresectable disease
can be managed without surgery.
The emergence of nonsurgical means of palliation has
underscored the importance of accurate preoperative staging
and selection of patients for attempted curative resection.
Candidates for attempts at curative surgery should have no
evidence of distant metastatic disease, and the tumor should
be amenable to complete extirpation based on a lack of
invasion into major vascular structures. Computed tomog-
raphy (CT) and, more recently, laparoscopy have become
indispensable for detecting intraabdominal metastatic dis-
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ease (20–25). Because CT is both noninvasive and a reliable
means of documenting distant disease, it is the preferred
initial procedure in any staging strategy. The detection of
tumor invasion of the portal and mesenteric vasculature has
traditionally relied on CT and mesenteric angiography (20,
22, 26–31). Endoscopic ultrasound (EUS) has emerged as
an innovative pancreatic imaging modality with an accuracy
of .90% in the local staging of pancreatic cancer (32–37).
Although EUS is limited as a means of detecting distant
disease, it compares favorably to angiography and CT for
defining vascular invasion and tumor size (33, 38, 39).
There is currently no consensus on the optimal preoper-
ative staging strategy for patients with adenocarcinoma of
the pancreas. Furthermore, the impact of individual staging
procedures on clinical and economic endpoints remains
unclear. Using decision analysis, we investigated the effect
of alternative staging strategies employed in clinical prac-
tice, incorporating EUS, angiography, and laparoscopy on
the clinical outcomes and disease-specific costs in patients
with pancreatic cancer.
MATERIALS AND METHODS
Computer-based models simulating the staging and treat-
ment of patients with adenocarcinoma of the pancreas were
created with Decision Maker (Pratt Medical Group, Boston,
MA). All patients entering the model were potential surgical
candidates with no evidence of unresectable disease on
dynamic CT. We chose dynamic as opposed to helical CT
scanning because of its widespread availability in the com-
munity, its frequent use in screening examinations, and the
ongoing debate regarding the magnitude of staging superi-
ority that helical scanning provides (40). We evaluated
seven alternative staging strategies representing popular
clinical practices:
1. LAP: Patients proceeded directly to laparoscopy and if
there was no evidence of intraabdominal dissemination,
full surgical exploration was performed with the intent of
undertaking a potentially curative resection.
2. ANG-LAP: Angiography was performed as the primary
staging procedure, and patients with resectable tumors
proceeded to laparoscopy followed by laparotomy for a
potentially curative resection as outlined in the LAP
strategy.
3. EUS-LAP: EUS was the primary staging procedure; if
the tumor seemed resectable, laparoscopy followed by
full surgical exploration was performed as in the LAP
strategy.
4. LAP-EUS: Laparoscopy was performed as the initial
procedure distinct from the planned laparotomy for pos-
sible curative resection. When laparoscopy revealed no
intraabdominal dissemination, the patient proceeded to
EUS and, if the tumor was deemed resectable, full sur-
gical exploration was performed.
5. LAP-ANG: If the initial laparoscopy revealed no intra-
abdominal dissemination, the patient proceeded to mes-
enteric angiography. If the tumor was resectable by an-
giographic criteria, full surgical exploration for a
potentially curative resection was performed.
6. ANG-EUS-LAP: Angiography was performed as the pri-
mary staging procedure and EUS was performed as a
confirmatory procedure only in patients with unresect-
able disease by angiography. If angiography or EUS
demonstrated a resectable tumor, laparoscopy was per-
formed followed by laparotomy when there was no ev-
idence of intraabdominal metastasis.
7. EUS-ANG-LAP: EUS was performed as the primary
staging procedure and angiography was performed as a
confirmatory procedure only in patients with unresect-
able disease by EUS. If EUS or angiography demon-
strated a resectable tumor, laparoscopy was performed
followed by laparotomy when there was no evidence of
intraabdominal metastasis. The last two strategies em-
ployed the confirmatory procedure as a means of mini-
mizing overstaging and, hence, limiting the allocation of
patients with resectable disease to palliative therapy.
Patients with unresectable disease determined by EUS, an-
giography, or laparoscopy were managed with endoscopic
stenting for obstructive jaundice, CT-guided biopsy to con-
firm a histological diagnosis of adenocarcinoma, and gas-
trojejunostomy if the patient developed duodenal obstruc-
tion. Patients with unresectable disease at laparotomy were
managed with surgical palliation, which included pancreatic
biopsy, choledochojejunostomy in the setting of obstructive
jaundice, and gastrojejunostomy when duodenal obstruction
was present or anticipated.
Clinical Inputs
All assumptions for clinical probabilities were derived from
critical analysis of the literature. Performance characteristics
for alternative staging procedures and disease natural his-
tory are outlined in Table 1.
Cost Inputs
All cost estimates were based on Medicare reimbursements
for our university-based hospital (Table 2). All staging
procedures and nonsurgical palliative procedures were as-
Table 1. Clinical Inputs
Clinical Variable Probability Range References
Angiography sensitivity* 0.70 0.70–1.00 20, 22,
26–33Angiography specificity* 0.91 0.70–1.00
EUS sensitivity* 0.91 0.70–1.00
32–39EUS specificity* 0.92 0.70–1.00
Laparoscopy sensitivity† 0.85 0.85–1.00
21–25Laparoscopy specificity† 1.00
Tumor resectability 0.33 21–23
Obstructive jaundice 0.80
Duodenal obstruction 0.10
* Detection of locally unresectable disease.
† Detection of intraabdominal dissemination (e.g., peritoneal or hepatic metasta-
sis).
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sumed to be outpatient procedures, as this is the current
standard at the majority of centers. All hospital, profes-
sional, pharmaceutical, and pathology fees were included.
Indirect costs (e.g., lost productivity) and nonmedical direct
costs (e.g., travel, lodging) were not included.
Analysis
The model simulated the evaluation and initial treatment
allocation of 100 patients with pancreatic adenocarcinoma
limited to the head of the pancreas on dynamic CT. Favor-
able clinical outcomes measured included surgical resection
for patients with resectable tumors and nonsurgical pallia-
tion for patients with unresectable disease. Missed oppor-
tunity for cure in patients with resectable disease and sur-
gical exploration for unresectable disease were considered
undesirable outcomes. Cost per curative resection was cal-
culated for each of the staging strategies. When one strategy
yielded a higher resection rate at an increased cost per
curative resection, an incremental cost–effectiveness ratio
(additional money spent per additional curative resection)
was calculated. Sensitivity analysis examined the impact of
varying the performance characteristics for staging tech-




The distribution of patients into the desirable (e.g., resect-
able and explored, unresectable and not explored) and un-
desirable (e.g., resectable and not explored, unresectable
and explored) clinical categories is represented in Table 3.
A strategy employing laparoscopy alone resulted in resec-
tion for all patients with resectable tumors, largely because
of the requirement of pathological confirmation of distant
disease to forestall resection. This level of precision, which
eliminated missed opportunities for cure, came at a cost of
nearly 40 surgical explorations in patients with unresectable
disease per 100 patients staged.
Both ANG-LAP and LAP-ANG appropriately identified
91% (30 of 33) of individuals with resectable disease; how-
ever, 13.2% of patients staged underwent an unnecessary
exploration. Strategies employing EUS followed by lapa-
roscopy (EUS-LAP) or laparoscopy followed by EUS
(LAP-EUS) similarly identified a slightly higher percentage
(92%) of patients amenable for cure but resulted in the
lowest rate of unnecessary surgical explorations (5.8% of
patients staged), a greater than 2-fold reduction relative to
angiography-based strategies and a 5-fold reduction relative
to laparoscopy alone. The strategies employing a confirma-
tory procedure when the initial EUS or angiography pre-
dicted unresectable disease further increased the resection
rate from 92% (30 of 33) to 99% (32 of 33); however, this
intervention to reduce missed opportunity for cure increased
the inappropriate exploration rate nearly 3-fold from 5.8%
to 15.5%.
Cost Analysis
Since the goal of staging is the accurate allocation of pa-
tients to curative resection and palliative interventions, the
economic analysis focused on the cost per curative resection
(Table 4). This cost–effectiveness ratio was lowest for the





Laparoscopy with biopsy $ 2,880
Angiography $ 1,720 $600–2,000
ERCP with biliary stent $ 1,330
CT-guided biopsy $ 760
EUS $ 660 $600–2,000
* Medicare reimbursement.
EUS 5 endoscopic ultrasound.
Table 3. Clinical Outcomes
Strategy









LAP 33.0% 27.4% 0.0% 39.6%
ANG-LAP 30.0% 53.8% 3.0% 13.2%
EUS-LAP 30.4% 61.2% 2.6% 5.8%
LAP-ANG 30.0% 53.8% 3.0% 13.2%
LAP-EUS 30.4% 61.2% 2.6% 5.8%
ANG-EUS-LAP 32.8% 51.5% 0.2% 15.5%
EUS-ANG-LAP 32.8% 51.5% 0.2% 15.5%
ANG 5 angiography; EUS5 endoscopic ultrasound; LAP5 laparoscopy. (For additional abbreviations, see Materials and Methods.)
Table 4. Cost Outcomes










Abbreviations as in Table 3.
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EUS-LAP strategy at $37,600. Reversing the order of stag-
ing procedures in the LAP-EUS strategy served only to
increase the cost per patient by $2,300 without altering the
outcomes, yielding a cost per curative resection of $45,300.
The ANG-LAP strategy increased the cost per patient by
$2,000 relative to the EUS-LAP strategy, resulting in a cost
per curative resection of $44,600. Dissection of the expen-
ditures within the model demonstrated that approximately
50% of this increased cost in the ANG-LAP strategy was
attributable to differences in staging procedure costs and
50% was due to an increase in unnecessary surgical explo-
rations. As with the EUS-based strategy, performing lapa-
roscopy before angiography served only to increase the
cost–effectiveness ratio to $51,200 without altering out-
comes. Laparoscopy alone was the least cost-effective strat-
egy, resulting in a cost per curative resection of $54,800, a
46% increase relative to the EUS-LAP strategy.
Both the EUS-ANG-LAP and ANG-EUS-LAP strategies
were associated with increased total cost per patient because
of added staging and surgical palliative costs, but the in-
crease in curative resections resulted in intermediate cost–
effectiveness ratios. The EUS-ANG-LAP strategy was cost-
effective relative to the ANG-EUS-LAP strategy with a cost
per curative resection of $42,800.
Because the laparoscopy strategy yielded the highest rate
of surgical resections yet required the greatest expenditures,
an incremental cost analysis was performed. The additional
resections realized in the LAP strategy came at an incre-
mental cost of $257,000 per additional curative resection
relative to the EUS-LAP strategy and $2,033,000 per addi-
tional curative resection relative to the EUS-ANG-LAP
strategy. Similarly, the improved resection rate in the EUS-
ANG-LAP strategy required $108,000 per additional cura-
tive resection relative to the EUS-LAP strategy.
Sensitivity Analysis
The EUS-LAP strategy remained the most cost-effective
strategy when the cost of EUS and angiography were varied
from $400 to $2000. The cost per curative resection was
also insensitive to alterations of the sensitivity or specificity
of EUS and angiography from 0.7 to 1.0.
DISCUSSION
Pancreatic cancer is among the most lethal of malignancies,
primarily because of the advanced stage at the time of
diagnosis. The vast majority of patients have incurable
disease, underscoring the importance of preoperative selec-
tion of patients for attempted resection. Patients with resid-
ual disease after resection have a median survival similar to
patients treated with palliative therapy (8, 10, 15). Further-
more, several randomized trials have demonstrated the
equivalent success and lower short-term mortality of non-
surgical palliation of obstructive jaundice relative to surgi-
cal interventions (16–18). Therefore, the higher rate of early
mortality and morbidity associated with surgical palliation
may be avoided in patients with advanced tumors if the
preoperative staging strategy accurately identifies patients
with unresectable disease. Similarly, to maximize clinical
benefit, efforts to avoid unnecessary surgical interventions
should not result in an excessive rate of overstaging, thereby
denying patients with resectable disease the possibility of
cure. Finally, there is also the concern that extensive pre-
operative imaging protocols increase expenditures without
affecting management or outcomes.
Dynamic CT is a noninvasive means of detecting unre-
sectable disease and should always be the initial imaging
procedure when staging adenocarcinoma of the pancreas.
Vascular invasion has traditionally been assessed with mes-
enteric angiography (41), but the emergence of other imag-
ing modalities such as EUS has led to controversy regarding
the optimal staging strategy for patients with pancreatic
cancer. Recently, laparoscopy has been employed as a more
sensitive means of detecting intraabdominal metastasis and
is logically employed before a full laparotomy. However,
some investigators have suggested laparoscopy as the initial
staging procedure after CT as a means of avoiding other
invasive imaging procedures such as angiography (23). Oth-
ers have questioned the need for any specialized imaging
procedure to evaluate for the presence of vascular invasion,
instead employing CT and laparoscopy alone before surgi-
cal exploration. Our model represents the first systematic
analysis of potential staging strategies incorporating these
imaging procedures.
Because the goal of any staging procedure is to accurately
allocate patients to appropriate treatment protocols based on
pathological stage at the time of evaluation, our clinical
endpoints of interest reflect this intention. The strategy
employing EUS followed by laparoscopy (EUS-LAP)
yielded the lowest rate of unnecessary surgical explorations
and a 2.6% rate of overstaging. This low rate of overstaging
translated into a surgical resection in 92% of patients with
resectable tumors. Both strategies employing angiography
as the sole method of detecting vascular invasion increased
both undesirable outcomes relative to the EUS strategies.
Because of the 100% specificity of laparoscopy with biopsy,
the strategy employing laparoscopy alone maximized the
number of resected patients. However, our model demon-
strates the cost of this benefit as a 5-fold increase in the
number of unnecessary surgical explorations in unresectable
patients. Both strategies employing a confirmatory proce-
dure produced a nearly perfect rate of identifying resectable
tumors while reducing the number of unnecessary explora-
tions by 61% relative to laparoscopy alone. Based on these
estimated clinical outcomes, strategies incorporating EUS
should be favored over strategies incorporating angiography
as a means of detecting vascular invasion. Similarly, if
minimizing missed opportunities for cure is prioritized,
strategies with a confirmatory procedure to evaluate for
vascular invasion (e.g., EUS-ANG-LAP) are preferred to
laparoscopy alone because of the significant reduction in
unnecessary explorations.
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In addition to projecting these clinical endpoints, our
analysis provides an estimate of the relative cost–effective-
ness of these staging protocols. The traditional strategy of
angiography followed by laparoscopy (ANG-LAP) yielded
a cost per curative resection of $44,600. Substituting EUS
for angiography yielded the most cost-effective strategy,
lowering the cost per curative resection by $7000 to
$37,600. Approximately one-half of this reduction was at-
tributable to reduced staging costs, and one-half was due to
a decrease in unnecessary explorations. Some have pro-
posed laparoscopy as the initial staging procedure before
specialized imaging procedures to define vascular invasion
(23). In our analysis, both LAP-EUS and LAP-ANG in-
creased the cost per curative resection without altering the
clinical outcomes relative to the EUS-LAP and ANG-LAP,
respectively. This increased cost is incurred because all
patients are subjected up-front to the relatively costly pro-
cedure of laparoscopy. Similarly, the EUS-ANG-LAP strat-
egy is preferred over the ANG-EUS-LAP strategy because
of the lower cost of the former with identical clinical out-
comes. The laparoscopy-alone (LAP) strategy proved to be
the least cost-effective. Although this strategy yielded a
slightly higher rate of curative resections, the incremental
cost of this benefit was $257,000 per additional curative
resection relative to the EUS-LAP strategy and $2,033,000
per additional curative resection relative to the EUS-ANG-
LAP strategy. Therefore, although laparoscopy alone pro-
vides a marginal increase in the number of patients under-
going surgical resection, policy makers and clinicians need
to consider the increased rate of unnecessary surgical ex-
plorations and incremental expenditures before adopting
this strategy.
Our analysis cannot be used to select one strategy as the
dominant strategy but, rather, provides a framework for
physicians, policy makers, and payers to select appropriate
staging algorithms given our current understanding of the
individual components of staging. In addition, our model
allows for the optimal design of future prospective studies
designed to clarify the role of specific staging algorithms by
avoiding strategies such as the angiography-based strate-
gies, which are clearly deleterious from a clinical and cost
perspective.
Our model has several limitations. All decision models
contain a level of uncertainty inherent in the clinical and
economic assumptions of the model. Sensitivity analysis
provides a means of addressing this uncertainty by assigning
a range of values to inputs prone to uncertainty. In our
analysis we specifically address the importance and relative
merits of specialized imaging procedures designed to detect
vascular invasion. The cost per curative resection was in-
sensitive to alterations in the cost and a wide range of
performance characteristics of EUS and angiography. We
examine the cost per curative resection as the primary eco-
nomic outcome, inasmuch as accurate patient allocation is
the primary goal of preoperative staging. It should be em-
phasized that our definition of curative resection is a patho-
logical cure at the time of resection. As the majority of these
patients eventually succumb to recurrent disease, these cost
estimates grossly underestimate the true cost per cure. An
index such as cost per life-year gained would be more useful
as a reference with other medical interventions such as the
treatment of hypertension; however, our goal was to directly
compare alternative staging strategies for pancreatic cancer.
Furthermore, obtaining these parameters would require an
estimate of survival attributable to accuratev rsusinaccu-
rate staging, and these figures are currently not available.
Our analysis assumes the payer’s perspective and, hence,
only direct costs are included. We believe that this provides
a conservative estimate of the relative cost–benefit analysis,
and institutes a bias in favor of less aggressive staging
strategies such as LAP, because the indirect costs are cer-
tainly higher for strategies with increased morbidity and
mortality from unnecessary surgical explorations.
Finally, we have not included certain innovative imaging
modalities such as helical CT, magnetic resonance imaging,
and laparoscopic ultrasound, as high quality data on the
performance characteristics for pancreatic cancer are still
limited. Preliminary data from our institution (42) and oth-
ers (43) supports the superiority of EUS relative to helical
CT for defining locally unresectable disease, and when these
results were incorporated into our model, strategies employ-
ing EUS remained cost-effective. These data support the
strategy employing an initial cross-sectional imaging tech-
nique to determine the absence of metastatic disease, fol-
lowed by a more sensitive technique such as EUS to deter-
mine local resectability. The adaptability of decision
analysis will permit us to incorporate new information into
the analysis as our knowledge of other imaging modalities
and interventions for pancreatic cancer advances.
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